Alteron is an early-stage pharmaceutical company focused on the development and commercialization of first-in-class TDP-43 inhibitors. Overexpression of TDP-43 are very toxic to mature neuronal and lung cells. Inhibiting it can benefit a huge population of patients with neurodegenerative disorders and cystic fibrosis, for which there is no disease modifing medicine on the market. Our candidate medicine has demonstrated superb safety and efficacy profile. Our team welcome new investors in sharing our vision for transforming the lives of people with limited or no options, so they can live their lives more fully.

Please contact us for more information.